Povorcitinib (INCB054707): JAK1 Inhibitor Discovery Data

Jincong Zhuo published data on the discovery of povorcitinib (INCB054707), an orally bioavailable and isoform-selective Janus kinase 1 (JAK1) inhibitor. The dataset, last updated on 2026-05-27, includes protein crystallography data in PDB format, totaling 175.2 KB. It supports the compound's development for treating inflammatory and autoimmune diseases.

Use Cases

• Analyze JAK1 vs. JAK2 selectivity based on protein crystallography data mentioned in the description
• Model pharmacokinetic properties based on the described amide moiety and hinge binding motif modifications
• Validate murine arthritis model efficacy results described in the dataset's supporting research

Strengths

• Includes protein crystallography data (PDB format) supporting the structural basis for JAK1 selectivity
• Dataset is focused on a single, well-described compound (povorcitinib/INCB054707) with a clear therapeutic rationale

Limitations

• Dataset size is very small (175.2 KB), indicating limited scope
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Jincong Zhuo via figshare

Collection Method

Likely contains experimental data from the compound discovery and characterization process described.

Freshness

Last updated 2026-05-27 20:10:58